The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled Trial
- 1 December 2010
- journal article
- research article
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 10 (6), 452-458
- https://doi.org/10.3816/cbc.2010.n.059
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cellsCancer Letters, 2010
- Metronomic administration of ibandronate and its anti-angiogenic effects in vitroMicrovascular Research, 2009
- The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitroBone, 2009
- Bisphosphonates: Mechanism of Action and Role in Clinical PracticeMayo Clinic Proceedings, 2008
- Adjuvant Trastuzumab Therapy for HER2-Positive Breast CancerClinical Breast Cancer, 2008
- Molecularly Targeted Therapy in Breast Cancer: The New GenerationRecent Patents on Anti-Cancer Drug Discovery, 2008
- Zoledronic AcidDrugs, 2008
- Mechanisms of Bone MetastasisThe New England Journal of Medicine, 2004
- Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.Journal of Clinical Oncology, 1998
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesThe New England Journal of Medicine, 1996